Empagliflozin Useful Second-Line for Diabetes vs GlimepirideEmpagliflozin Useful Second-Line for Diabetes vs Glimepiride
The SGLT2 inhibitor empagliflozin provided favorable results at 2 years compared with the sulfonylurea glimepiride when used as second-line therapy after metformin in diabetes. Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
More News: Diabetes | Empagliflozin | Endocrinology | Fortamet | Glimepiride | Jardiance | Metformin | SGLT2 Inhibitors